Weekly Digest - July 2025

Weekly Digest - July 2025

02 July 2025: Biokin, having landed BMS deal, posts Phase 3 cancer win for bispecific ADC

  • Biokins Phase 3 trial of its bispecific ADC, Izalontamab brengitecan (iza-bren), met at least one primary endpoint in patients with recurrent or metastatic nasopharyngeal carcinoma
  • The ADC targets EGFR and HER3, delivering a cytotoxic payload to epithelial tumor cells expressing these receptors
  • Bristol Myers Squibb licensed ex-China rights to iza-bren in 2023 for $800 million upfront, with the total deal potentially worth up to $8.4 billion

For full story click  here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home